Arylsulfatase B (ASB) Test
🧬 Arylsulfatase B (ASB) Test
A Complete Clinical Guide for Diagnosing MPS VI (Maroteaux-Lamy Syndrome)
1. What Is Arylsulfatase B (ASB)?
Arylsulfatase B (ASB), also known as N-acetylgalactosamine-4-sulfatase, is a lysosomal enzyme responsible for breaking down dermatan sulfate (DS).
A deficiency of ASB leads to dermatan sulfate accumulation, which is the hallmark of Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome).
ASB is encoded by the ARSB gene located on 5q11–q13, and multiple pathogenic variants have been reported.
2. Clinical Purpose of ASB Testing
✔ 1) Confirmatory diagnosis of MPS VI
- Severely reduced ASB activity → DS accumulation → classic MPS VI phenotype
- Used across infants, children, and adult presentations
✔ 2) Follow-up for positive GAG screening
- Elevated urinary GAGs, especially dermatan sulfate, requires enzymatic confirmation
✔ 3) Carrier testing
- Useful for genetic counseling in families with known ARSB mutations
✔ 4) Newborn or early childhood screening
- In some regions, ASB is evaluated from dried blood spot samples
3. Testing Methods (Focus on Enzymatic Assay)
The standard method for ASB measurement is quantitative enzymatic assay using substrates such as 4-methylumbelliferyl (4-MU)-based sulfate compounds.
🔹 1) Leukocyte Enzyme Assay (Gold Standard)
- Peripheral blood → Isolated leukocytes
- Measures fluorescence of 4-MU released after substrate cleavage
- Most accurate for diagnosing MPS VI
🔹 2) Fibroblast Enzyme Assay
- Skin biopsy → Cultured fibroblasts → ASB activity measurement
- Used when blood results are equivocal or require verification
🔹 3) Dried Blood Spot (DBS) Enzyme Testing
- Used in screening, particularly newborns
- Lower sensitivity/specificity → not confirmatory
🔹 4) Molecular Genetic Test
- ARSB gene sequencing
- Distinguishes pathogenic variants from benign polymorphisms (pseudodeficiency)
4. Reference Range
Values vary by laboratory, but a common example is:
Leukocyte ASB enzyme activity:
1.5 – 5.0 nmol/min/mg protein
Each laboratory should use its validated reference interval.
5. Clinical Significance
✔ 1) Pathogenic Deficiency → MPS VI
Low ASB activity leads to dermatan sulfate accumulation, causing:
- Dysostosis multiplex
- Joint stiffness and contractures
- Coarse facial features
- Cardiac valve disease
- Hepatosplenomegaly
- Restrictive lung disease
- Intelligence is typically preserved, differentiating it from MPS I or II
✔ 2) Pseudodeficiency
- ASB activity may appear partially low
- No dermatan sulfate accumulation
- No clinical disease
- Requires genetic confirmation + urinary GAG testing
6. Conditions Associated With Decreased ASB Activity
| Category | Condition | Key Features |
|---|---|---|
| Primary deficiency | MPS VI (Maroteaux-Lamy syndrome) | ARSB mutations, dermatan sulfate accumulation |
| Pseudodeficiency | ARSB benign variants | Partial enzyme reduction without disease |
| Rare secondary changes | Other LSDs | Very infrequent; not typically diagnostic |
7. Interpreting ASB Test Results
✔ ASB <10% of normal
- Strongly suggests MPS VI
- Urinary GAG: DS elevation
- Perform ARSB genetic testing
✔ ASB 20–50% of normal
- Possible carrier or pseudodeficiency
- Check symptoms, family history, and ARSB genotype
✔ Normal ASB
- MPS VI excluded
- Consider evaluation for other types of MPS if symptoms persist
8. Important Interpretation Considerations
- Pseudodeficiency must always be ruled out
ASB alone cannot confirm MPS VI. - Leukopenia can falsely lower enzyme activity
→ Ensure adequate leukocyte count in specimen - Substrate specificity varies by kit
→ Some 4-MU substrates may have non-specific reactions - Pre-analytic factors matter
- Heat exposure
- Delayed transport
- Sample degradation
- DBS is screening only
Confirmatory diagnosis must be performed in leukocytes or fibroblasts.
9. Conclusion
ASB enzyme testing is the essential diagnostic tool for MPS VI, and the leukocyte enzymatic assay remains the gold standard.
However, enzyme activity alone cannot establish a definitive diagnosis.
Accurate diagnosis requires the combined approach of:
✔ ASB enzyme assay
✔ Urinary GAG (dermatan sulfate) analysis
✔ ARSB gene sequencing
From a laboratory medicine perspective, ASB testing exemplifies the importance of integrating biochemical results, genetic analysis, and pre-analytic quality control for accurate diagnosis.
📚 References
- Harmatz P, et al. Mucopolysaccharidosis VI: Clinical features and diagnostic strategies. Mol Genet Metab.
- Valayannopoulos V. Enzymatic diagnosis of mucopolysaccharidoses. Orphanet J Rare Dis.
- Clarke LA. ARSB gene and MPS VI: Genotype–phenotype correlations.
- WHO. Laboratory guidelines for lysosomal storage diseases.
- Guffon N. MPS VI biochemical diagnosis: Enzyme assays and pitfalls.
- ClinVar / HGMD – ARSB Variant Database.